Anna Rea: Enhancing human NK cell antitumor function by knocking out SMAD4
Anna Rea, Strategic Clinical Development Specialist at MEDSIR, posted on LinkedIn about recent paper she and colleagues co-authored:
“Fantastic news!
I am beyond excited and proud to finally share that our paper ‘Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression’, based on the research from my PhD thesis, has been published today in Nature Immunology journal! This is truly a milestone for me!
In this work, we explored the knockout of the common signaling mediator SMAD4 by CRISPR–Cas9 that resulted in NK cells with enhanced antitumor activity, offering a new strategy for improving NK cell-based cancer immunotherapies.
It’s been an incredible journey, and I am grateful to my supervisor Aura Muntasell and my co-authors, Sara Santana Hernández, Marta Sanvicente García, Mariona Cabo Ester, Jesús Suárez Olmos, and everyone else who contributed along the way. I’m only tagging a few, but this was truly a team effort—huge thanks to all who supported this work!”
Authors: Anna Rea, Sara Santana-Hernández, Javier Villanueva, Marta Sanvicente-García, Mariona Cabo, Jesús Suarez-Olmos, Fabricio Quimis, Mengjuan Qin, Eduard Llorens, Sandra Blasco-Benito, Lamberto Torralba-Raga, Lorena Perez, Bishan Bhattarai, Elisenda Alari-Pahissa, Anna-Maria Georgoudaki, Francesc Balaguer, Manel Juan, Julián Pardo, Toni Celià-Terrassa, Ana Rovira, Nina Möker, Congcong Zhang, Marco Colonna, Jan Spanholtz, Aura Muntasell
Read more about NK cells on oncodaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023